Latest pharmaceutical approaches across the spectrum of heart failure
Heart Failure Reviews · 2024
DOI: 10.1007/s10741-024-10389-8 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Heart Failure Reviews, 2024. Verfasst von Dimitrios Bismpos und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine III, Cardiology, Angiology and Intensive Care Medicine, University Hospital, Saarland University, Homburg, Saar, Germ…. Hauptthemen laut MEDLINE: Heart Failure. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 92 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsklinikum des Saarlandes und Medizinische Fakultät der Universität des Saarlandes.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Despite major advances in prevention and medical therapy, heart failure (HF) remains associated with high morbidity and mortality, especially in older and frailer patients. Therefore, a complete, guideline-based treatment is essential, even in HF patients with conditions traditionally associated with a problematic initiation and escalation of the medical HF therapy, such as chronic kidney disease and arterial hypotension, as the potential adverse effects are overcome by the overall decrease of the absolute risk. Furthermore, since the latest data suggest that the benefit of a combined medical therapy (MRA, ARNI, SGLT2i, beta-blocker) may extend up to a LVEF of 65%, further trials on these subgroups of patients (HFmrEF, HFpEF) are needed to re-evaluate the guideline-directed medical therapy across the HF spectrum. In particular, the use of SGLT2i was recently extended to HFpEF patients, as evidenced by the DELIVER and EMPEROR-preserved trials. Moreover, the indication for other conservative treatments in HF patients, such as the intravenous iron supplementation, was accordingly strengthened in the latest guidelines. Finally, the possible implementation of newer substances, such as finerenone, in guideline-directed medical practice for HF is anticipated with great interest.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine III, Cardiology, Angiology and Intensive Care Medicine, University Hospital, Saarland University, Homburg, Saar, Germany. dimbismp@gmail.com.
- Department of Internal Medicine II, Cardiology and Angiology, Marien Hospital Herne, University Clinic of the Ruhr University, Bochum University, Herne, Germany. dimbismp@gmail.com.
- Department of Internal Medicine III, Cardiology, Angiology and Intensive Care Medicine, University Hospital, Saarland University, Homburg, Saar, Germany.
Förderung
- Universitätsklinikum des Saarlandes und Medizinische Fakultät der Universität des Saarlandes
Zitieren
APA
Bismpos, D., Wintrich, J., Hövelmann, J., & Böhm, M. (2024). Latest pharmaceutical approaches across the spectrum of heart failure. Heart Failure Reviews. https://doi.org/10.1007/s10741-024-10389-8
Vancouver
Bismpos D, Wintrich J, Hövelmann J, Böhm M. Latest pharmaceutical approaches across the spectrum of heart failure. Heart Failure Reviews. 2024. doi:10.1007/s10741-024-10389-8
BibTeX
@article{Bismpos2024,
author = {Bismpos, Dimitrios and Wintrich, Jan and Hövelmann, Julian and Böhm, Michael},
title = {Latest pharmaceutical approaches across the spectrum of heart failure},
journal = {Heart Failure Reviews},
year = {2024},
doi = {10.1007/s10741-024-10389-8}
}
EUVIMED